Today, drug-based tumor therapies are generally carried out on an outpatient basis. In our oncology outpatient clinic, we treat patients who have been diagnosed with breast, ovarian, uterine or other rare gynecological cancers.

Our range of therapies includes

• chemotherapy
• anti-hormonal therapy
• Immunotherapy (e.g. immune checkpoint inhibitors)
• antibody therapy (e.g. trastuzumab, bevacizumab) and
• "targeted therapy", i.e. targeted therapy with "biologicals" (e.g. parp inhibitors).

In addition, we can offer a wide range of clinical studies from various national and international study groups, giving you access to the latest treatment methods . Our study center ensures the best possible implementation of the strict guidelines and high requirements of a clinical study.

The loss of hair during chemotherapy means additional psychological stress and stigmatization for many women. Not infrequently, the fear of losing hair is even a reason for some patients not to undergo the necessary chemotherapy. Cooling the scalp during chemotherapy with the DigniCapTM system promises to minimize hair loss so that patients can dispense with other head coverings (wig, headscarf).

During the administration of cytostatic drugs, the scalp temperature is regulated to 4°. The patient wears a silicone cap on her head, which is cooled. For this purpose, a coolant from the DigniCap® system's climate control unit circulates through the silicone cap.

The assumed mode of action is based on three mechanisms:

1. Cooling leads to a constriction of the blood vessels in the scalp, thereby reducing the amount of medication that reaches the hair roots.
2. The absorption of the medication into the hair cells can be reduced by the low temperatures, thereby reducing the concentration of medication.
3. Scalp cooling can reduce the mode of action/effect of the medication and thus also its activity at the hair root.

These mechanisms reduce the effect of the cytostatic drugs on the hair roots, which reduces hair loss.
Short-term and mild side effects such as headaches, feeling cold and dizziness are possible. In our experience, however, scalp cooling is generally well tolerated by users.

Costs:

Scalp cooling is not a health insurance benefit, but an individual health service (IGeL) that must be paid for by the users themselves.

We would like to thank the Roparun Foundation and the Rudolf Bartling Foundation for their donations. As a result, the costs for the treatment can currently be offered at a reduced rate.